Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Right On Brands Acquires 49% Interest in Neuro Science Research Centers

Right On Brands, Inc.

McapMediaWire -- Right on Brands, Inc. (OTC: RTON ), a leader and innovator of HEMP DERIVED, and WELLNESS products announced today that its Board of Directors has approved an investment in Neuro Science Research Centers Inc. Neuro Science Research Centers Inc. was formed to be one of the first licensed Psilocybin extraction facilities in Oregon. Psilocybin is being used to treat mental disorders and is shown to be of great benefit. The Johns Hopkins Center for Psychedelic and Consciousness Research is leading the way in exploring innovative treatments using psilocybin. The molecular structure of psilocybin, a naturally occurring psychedelic compound found in 'magic mushrooms,' allows it to penetrate the central nervous system and the scientific and medical experts are just beginning to understand its effects on the brain and mind and its potential as therapeutics for mental illnesses. Many other researchers and companies are looking to use these new products that will come from Psilocybin. Jerry Grisaffi, President, and CEO of Right on Brands, stated, “We are excited to be entering into this relationship and partnership with Neuro Science Research Centers. Psilocybin research is still in its infancy, but with the level of production already accomplished and continued acceptance within the medical community using psilocybin, we believe this is an opportunity for us to be on the ground level, yet with our locations and distribution network we will be able to attain early success within a reasonable timeframe.” Russel Young has been named President of the new entity and majority shareholder Mike Brown has been name Secretary and Director. “This is a great opportunity, and I too am excited about our relationship with Right on Brands Inc.” states Russel. About Us Right on Brands, Inc., is a consumer goods company specializing in the brand development and distribution of hemp-based foods, beverages, smokables, oils and topical products. Right on Brands, Inc. is a developer of a broad line of hemp-based smokables, beverages, tinctures, and topical products including products infused with CBD, Delta-8, Delta-10, THCV, CBDV, and Delta-9 (below the federal limit) and the all new HHC vapes, gummies and tinctures. We will also be launching a Kratom gummy. About ENDO Brands: ENDO Brands™, Humbly Hemp®, and ENDO Dispensary & Wellness™ Endo Franchise Group Inc, all share the same goal of providing our customers with the best products in the health and wellness space. As the field of health and wellness Endo’s approach is to give their customer a holistic approach to their wellness. To learn more, please visit: https://rightonbrands.com / www.endobrands.com / www.ENDOdispensaryrowlett.com Corporate Sales Contact: Mike Brown (214) 299-9528 / mike@rightonbrands.com ENDO Brands Corporate Store: ENDO Brands at Lakeview Plaza 6501 Dalrock Road Suite 100 Rowlett, Texas 75089 214-299-9528 AUSTIN LOCATION 12412 Limerick Avenue, Austin, Texas 78758 www.endoofaustin.com 512-621-0649 LAREDO LOCATION ENDO Laredo 2413 Jacaman Rd Laredo, Texas www.endolaredo.com 956-568-2300 HOUSTON LOCATION 3301 Louetta Rd Ste 109 Spring, Texas 77388 832-583-5383 (Website coming soon) MIAMI FLORIDA LOCATION 10850 SW 104 th St, Miami, Florida 33156 www.endo-miami.com 786-703-1276 PLANO LOCATION 601 W. Parker Road, Plano, Texas 75023 469-366-9694 DALLAS LOCATION 9585 Scyene Road, Dallas. Texas, (Website coming soon) Forward-Looking Statements This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the SEC. The forward-looking information provided herein represents the Company's estimates as of the date of this press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release. Investor Relations Contact Andrew Barwicki 516-662-9461 / andrew@barwicki.com Contact Details Mike Brown mike@rightonbrands.com Company Website https://rightonbrands.com/

April 12, 2023 09:00 AM Eastern Daylight Time

News Release

Freedom Holdings Releases Corporate Update

FREEDOM HLDG INC.

McapMediaWire -- Freedom Holdings, Inc. aka Freedom Acquisition Corp (OTC: FHLD ) (“FHLD” or the "Company”), is pleased to announce Freedom Holdings new management has completed the last 10Q bringing the company audits and filings completely current and up to date. The Company is now listed on OTC Markets as “PINK CURRENT” and is now working on its new 15c211 and planning on being listed as QB on OTC Markets. Management also confirmed that the Company is in final negotiations with potential acquisition candidates and will be bringing further updates in the very near future regarding the further development of it business plan. Press Release Contact: John Vivian CEO Freedom Holdings, Inc. 813-699-4098 Safe Harbor Statement This press release contains statements, which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details Freedom Holdings, Inc. +1 813-699-4098

April 11, 2023 11:30 AM Eastern Daylight Time

Canada Celebrates National Medical Laboratory Week

Canadian Society for Medical Laboratory Science

Since the onset of the COVID-19 pandemic, many of us have a better understanding of the laboratory’s role in testing, diagnosis and treatment of diseases. However, visible or not, medical laboratory professionals have always been a part of the health care team. Every day they provide answers for diagnosis and treatment for everything from diabetes, heart attacks, cancer and, of course, COVID-19 and all its variants. From April 9–15, 2023, Canada will celebrate these incredible health professionals during National Medical Laboratory Week (Lab Week). This national celebration is a time to recognize the valuable contributions that medical laboratory technologists (MLTs) and medical laboratory assistants (MLAs) make to patient care every single day. This week is aligned with International Biomedical Laboratory Science Day on April 15, a day of recognition for medical laboratory professionals across the globe. As part of this celebration, the Canadian Society for Medical Laboratory Science (CSMLS) is asking Canadians to see the lab, and the professionals who so often work behind the scenes. “Even though so many medical lab professionals work behind closed doors, away from patients, their work is vital to our health and wellbeing,” says CSMLS CEO Christine Nielsen. “Lab Week is the perfect time to stop and recognize their contributions to health care. Every day, lab professionals work diligently to provide accurate and precise results for patients, regardless of where they are. We know a patient is behind every sample.” Light displays by buildings and monuments across the country will shine a spotlight on the profession and bring Canada together for Lab Week. More than 24 sites will be lit up in indigo as a symbol of our collective appreciation for our medical laboratory professionals. A schedule of the light displays can be found at labweek.csmls.org. Photos will be shared via CSMLS social media: @csmls on Facebook and Twitter and @csmls_scslm on Instagram. “Lab Week is just one week to celebrate the amazing health care professionals who work 365 days of the year,” says CSMLS President, Michele Sykes. “They’ve processed millions of COVID-19 tests on top of the other million tests patients need for diagnosis, treatment and recovery. Medical lab professionals deserve massive thanks and respect all year long.” Medical Laboratory Technologists, Diagnostic Cytology Technologists, Clinical Genetics Technologists and Medical Laboratory Assistants are all part of the medical laboratory community across Canada. To learn more about their specialized work and their impact on patient care, visit https://medlabprofessionals.ca/. The Canadian Society for Medical Laboratory Science is the national certifying body for medical laboratory technologists and medical laboratory assistants, and the national professional society for Canada's medical laboratory professionals. Incorporated in 1937 as the Canadian Society of Laboratory Technologists, the society has over 14,000 members in Canada and in countries around the world. For more information about the CSMLS, visit: csmls.org. Contact Details CSMLS Michael Grant, Director, Marketing & Communications michaelg@csmls.org

April 10, 2023 09:00 AM Eastern Daylight Time

Mental Health Provider Shortage Needs Integrated Approach

The Chicago School of Professional Psychology

One of two people who need mental health services don’t get it and more than one in three Americans live in a region where there are not enough mental health providers to serve the population.* The average wait time for a medical doctor’s appointment is up to 26 days, up 24 percent since 2004 and there is a projected shortage of 48,000 primary care physicians in the U.S. by 2034.+ “ At a time when the U.S. faces a severe shortage of mental health providers, many people are also finding it increasingly difficult to get the medical care they need,” said Dr. Michele Nealon, Psy.D., President of The Chicago School of Professional Psychology. “There is a way for society to address both these problems and that is to integrate the health care system so that primary care and mental health professionals work as a team to treat the whole person more efficiently and effectively,” she said. “We need to take a community-focused, patient-centered, and holistic view approach to mental and physical healthcare,” said Dr. Nealon explained. “Many physical ailments put us at risk for psychological disorders and vice versa, so it makes sense for mental health professionals to work closely with medical doctors to treat the patient when they initially present with symptoms, rather than waiting for a referral later.” “For example, if you have trouble sleeping or your child is experiencing frequent stomach aches, you might turn to your doctor for help. The problem may be physical, yet too often, there are psychological factors such as stress, anxiety or depression that are at play,” Dr. Nealon said. “At The Chicago School, we are always thinking about how to view humans as part of a larger system—how individuals relate to their family, culture and community,” she explained. “That’s why we are dedicated to educating culturally competent psychologists and counselors who get hands-on training in their communities.” The Chicago School of Professional Psychology’s seven campuses nationwide educates 6,000 students, 70 percent of whom identify as people of color. *Mental Health America https://mhanational.org/issues/state-mental-health-america +American Academy of Family Physicians https://www.aafp.org/pubs/fpm/blogs/inpractice/entry/wait-times.html About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

April 07, 2023 11:59 AM Pacific Daylight Time

Chill Brands Group gives itself "really good growth capital" with latest fundraise

Chill Brands Group PLC

Chill Brands Group PLC (LSE:CHLL, OTCQB:CHBRF) CEO Callum Sommerton speaks to Proactive after announcing a £2.6mln fundraise that he says provides the company with "really good growth capital". Sommerton also talks about the company's expansion into nicotine-free vaping, something he sees as serious growth opportunity in a changing market. Contact Details UK Editorial +44 20 7989 0813 uk@proactiveinvestors.com

April 06, 2023 09:55 AM Eastern Daylight Time

Video

Destiny Pharma upbeat on prospects for C. Difficile treatment

Destiny Pharma PLC

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile treatment platform NTCD-M3 were published in the Microbiology Spectrum journal. Love explains what makes the platform so promising from Destiny's point of view, before going on to reveal more about the plans for bringing NTCD-M3 to the market. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 06, 2023 09:53 AM Eastern Daylight Time

Video

Aqua Cultured Foods Closes $5.5M Seed Round led by Stray Dog Capital

AquaCultured Foods

Food tech startup Aqua Cultured Foods today announced it has raised $5.5 million in seed funding to bring its ultra-realistic seafood alternatives to market. The round was led by Stray Dog Capital, a venture capital fund specializing in alternative protein investments, with participation from H Venture Partners, Aztec Capital Management and Amplifica Capital, along with follow-on investment from current investors Supply Change Capital, Big Idea Ventures, HPA, Aera VC, Kingfisher Family Investments, and Swiss Pampa. The round also included a strategic investment from CJ CheilJedang, a South Korea-based global food and bio company owning renowned brands such as Bibigo. Aqua will use the investment to equip its new facility, scale up production, bring products to market, add key talent, and expand its roster of restaurant and foodservice outlets for product introductions this year. “We appreciate having mission-aligned partners that offer strong strategic value for the next phase of our growth, which will involve building up the business and brand,” said Anne Palermo, CEO of Aqua. “Being good stewards of investor capital is important to us, so along with hitting milestones earlier than expected, we are benefiting from government programs, academic resources, and other advantages to get to market quickly.” Aqua’s primary value is its low cost of scaling and its path to price parity, thanks to proprietary fermentation methods that use relatively affordable inputs and equipment. The company recently acquired a food-grade facility that was already built out nearly to its requirements—which it estimates will save more than a million dollars in construction costs. Aqua was recently accepted into the Illinois Office of Business Development’s EDGE program that provides tax incentives to growing companies, which will save hundreds of thousands of dollars in taxes over the next 10 years. “The adage is true that early-stage funds heavily weight investment conviction in people, and less in technologies or products given the embryonic nature of companies at these stages, but Aqua already boasts strength across its team, product, and key partnerships already in place,” said Johnny Ream, Partner at Stray Dog Capital. “We are interested in backing founding teams leveraging unique technologies and approaches that drive a more sustainable future; the work Aqua is doing with alt-seafood has immense potential to drive both human and planetary benefits in a massive $100B+ global market.” The global plant-based seafood market was valued at $42.1 million in 2021, and is projected to reach $1.3 billion by 2031 with a CAGR of more than 42 percent as wild fish stocks are further depleted. In addition to depleted fish populations, commercial fishing practices result in damage to ecosystems, plastic waste, and “bycatch” of non-target species. As fish farming increases, so does habitat destruction, pollution and diseases spread to wild fish, and the industry’s reliance on antibiotics and wild-caught fish for feed. Despite its health halo, fish contains microplastics, mercury, pesticides, antibiotics, dioxin and PCBs. High in cholesterol and saturated fats, seafood, in particular finfish, is a good source of foodborne illness caused by bacteria, viruses and parasites. Aqua is developing calamari, shrimp, scallops, and filets of tuna and whitefish with proprietary mycoprotein fermentation processes that do not use any animal inputs, genetic altering or modification. Unlike plant-based processed foods formulated with starches and protein isolates, Aqua’s alt-seafood retains its naturally occurring fiber, protein, and other micronutrients. The company also produces minced “seafood” fillings for applications such as dumplings, ravioli, and sushi rolls. For images visit https://app.box.com/s/wfbrvgraf2ty2b7by5h6ahjsaqrd8zx3. Follow Aqua Cultured Foods LinkedIn https://www.linkedin.com/company/aquacultured-foods Instagram https://www.instagram.com/aquaculturedfoods Facebook https://www.facebook.com/AquaCulturedFoods Twitter https://twitter.com/eatAquaFoods ‎ About Aqua Cultured Foods Aqua Cultured Foods is an innovative food technology startup developing the world’s first whole-muscle cut seafood alternatives created through microbial fermentation. Its novel technology produces a sustainable, complete protein source using only a fraction of the resources required by traditional aquaculture. As an R&D company with a focus on product commercialization, Aqua Cultured Foods occupies a unique position in the burgeoning alt-seafood market as well as within the fermentation industry. The company’s mission is to mitigate global challenges such as overfishing, climate change and feeding the world’s expanding population with delicious, nutrient-rich foods. For more information visit https://www.aquaculturedfoods.com. About Stray Dog Capital Stray Dog Capital is a venture capital fund investing in innovative, early-stage companies across the food, beverage, and biotechnology sectors that are driving a healthier, humane, and more sustainable future. Stray Dog Capital supports its portfolio of investments with broad experience from its team as entrepreneurs, operators, advisors, and investors. www.straydogcapital.com. ### Contact Details Gary Smith +1 818-783-0569 gary@evolotuspr.com Company Website https://www.aquaculturedfoods.com

April 06, 2023 09:05 AM Eastern Daylight Time

Image

Futura Medical "confident of getting FDA approval this quarter"

Futura Medical PLC

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Proactive following the release of full year results for 2022. Barder says that despite losses, revenues "are now rapidly coming over the horizon" and he suggests "the last two years have been very very good for us". He adds that he's "confident of getting FDA approval for MED3000 this quarter" Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 06, 2023 06:12 AM Eastern Daylight Time

Video

Faron Pharmaceuticals moving "into next phase" with new CFO

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief financial officer James O'Brien speaks to Proactive on his second day in the new role. O'Brien reveals more about what he believes he can bring to Faron, highlighting his experience in the US capital markets. He adds that Faron is now moving "into [its} next phase of growth." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 06, 2023 05:27 AM Eastern Daylight Time

Video

1 ... 116 117 118 119 120 ... 250